– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...

The fear of cancer stems from the dread that it can recur at any time, even after treatment. A South Korean research team has ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the development ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

The transcriptional repressor B-cell lymphoma 6 (BCL6) plays a central role in the development and progression of various B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), where ...

Astrazeneca plc has provided data for their CD22-targeting antibody-drug conjugate (ADC) AZD-4512 under development for the treatment of B-cell malignancies, which still have significant rates of ...

The ongoing phase I/II clinical trial is evaluating the safety, tolerability and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001 Preliminary findings include a ...